{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:23:58Z","timestamp":1793838238346,"version":"4.6.1"},"reference-count":50,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1P50CA168536-01A1"],"award-info":[{"award-number":["1P50CA168536-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA175732-01"],"award-info":[{"award-number":["R01 CA175732-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0517-0","type":"journal-article","created":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T08:04:10Z","timestamp":1549440250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics"],"prefix":"10.1136","volume":"7","author":[{"given":"Andressa S.","family":"Laino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. C.","family":"Betts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Veerapathran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Dolgalev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sarnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. N.","family":"Quayle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. S.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. S.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,2,6]]},"reference":[{"key":"517_CR1","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.4049\/jimmunol.174.4.2021","volume":"174","author":"N Kienzle","year":"2005","unstructured":"Kienzle N, Olver S, Buttigieg K, Groves P, Janas ML, Baz A, Kelso A. Progressive differentiation and commitment of CD8+ T cells to a poorly cytolytic CD8low phenotype in the presence of IL-4. J Immunol. 2005;174:2021\u20139.","journal-title":"J Immunol"},{"key":"517_CR2","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1158\/2326-6066.CIR-14-0232","volume":"3","author":"SL Shiao","year":"2015","unstructured":"Shiao SL, Ruffell B, DeNardo DG, Faddegon BA, Park CC, Coussens LM. TH2-polarized CD4(+) T cells and macrophages limit efficacy of radiotherapy. Cancer Immunol Res. 2015;3:518\u201325.","journal-title":"Cancer Immunol Res"},{"key":"517_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1084\/jem.20101876","volume":"208","author":"L Monte De","year":"2011","unstructured":"De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, Braga M, Di Carlo V, Doglioni C, Protti MP. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med. 2011;208:469\u201378.","journal-title":"J Exp Med"},{"key":"517_CR4","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/intimm\/dxp095","volume":"21","author":"S Sakaguchi","year":"2009","unstructured":"Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? Int Immunol. 2009;21:1105\u201311.","journal-title":"Int Immunol"},{"key":"517_CR5","doi-asserted-by":"publisher","first-page":"4911","DOI":"10.1128\/JVI.77.8.4911-4927.2003","volume":"77","author":"EJ Wherry","year":"2003","unstructured":"Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol. 2003;77:4911\u201327.","journal-title":"J Virol"},{"key":"517_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/ni.1679","volume":"10","author":"SD Blackburn","year":"2009","unstructured":"Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, Betts MR, Freeman GJ, Vignali DA, Wherry EJ. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10:29\u201337.","journal-title":"Nat Immunol"},{"key":"517_CR7","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","volume":"27","author":"EJ Wherry","year":"2007","unstructured":"Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, Subramaniam S, Blattman JN, Barber DL, Ahmed R. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 2007;27:670\u201384.","journal-title":"Immunity"},{"key":"517_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1868-7083-4-5","volume":"4","author":"GP Delcuve","year":"2012","unstructured":"Delcuve GP, Khan DH, Davie JR. Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics. 2012;4:5.","journal-title":"Clin Epigenetics"},{"key":"517_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/CMR.0b013e328364c0ed","volume":"23","author":"DM Woods","year":"2013","unstructured":"Woods DM, Woan K, Cheng F, Wang H, Perez-Villarroel P, Lee C, Lienlaf M, Atadja P, Seto E, Weber J, et al. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Res. 2013;23:341\u20138.","journal-title":"Melanoma Res"},{"key":"517_CR10","doi-asserted-by":"crossref","unstructured":"Woods DM, Sodre AL, Villagra A, Sarnaik A, Sotomayor EM, Weber J. HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade. Cancer Immunol Res. 2015.","DOI":"10.1158\/2326-6066.CIR-15-0077-T"},{"key":"517_CR11","doi-asserted-by":"publisher","first-page":"6558","DOI":"10.18632\/oncotarget.2289","volume":"5","author":"M Kroesen","year":"2014","unstructured":"Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, Adema GJ. HDAC inhibitors and immunotherapy; a double edged sword? Oncotarget. 2014;5:6558\u201372.","journal-title":"Oncotarget"},{"key":"517_CR12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","volume":"348","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348:62\u20138.","journal-title":"Science"},{"key":"517_CR13","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/nmeth.2688","volume":"10","author":"JD Buenrostro","year":"2013","unstructured":"Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat Methods. 2013;10:1213\u20138.","journal-title":"Nat Methods"},{"key":"517_CR14","unstructured":"Deborah JL, Wong AR, Avramis E, Matsunaga DR, Komatsubara KM, Atefi MS, Escuin-Ordinas H, Chodon T, Koya RC, Ribas A, Comin-Anduix B. Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function. Cancer Immunol Res. 2014."},{"key":"517_CR15","doi-asserted-by":"crossref","unstructured":"Huang P, Almeciga-Pinto I, Jarpe M, van Duzer JH, Mazitschek R, Yang M, Jones SS, Quayle SN. Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models. Oncotarget. 2016.","DOI":"10.1158\/1535-7163.TARG-15-A187"},{"key":"517_CR16","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","volume":"119","author":"L Santo","year":"2012","unstructured":"Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 2012;119:2579\u201389.","journal-title":"Blood"},{"key":"517_CR17","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/nm1652","volume":"13","author":"R Tao","year":"2007","unstructured":"Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM, Li B, Turka LA, Olson EN, Greene MI, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med. 2007;13:1299\u2013307.","journal-title":"Nat Med"},{"key":"517_CR18","doi-asserted-by":"publisher","first-page":"4571","DOI":"10.1073\/pnas.0700298104","volume":"104","author":"B Li","year":"2007","unstructured":"Li B, Samanta A, Song X, Iacono KT, Bembas K, Tao R, Basu S, Riley JL, Hancock WW, Shen Y, et al. FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc Natl Acad Sci U S A. 2007;104:4571\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"517_CR19","doi-asserted-by":"publisher","first-page":"ra45","DOI":"10.1126\/scisignal.2002873","volume":"5","author":"UH Beier","year":"2012","unstructured":"Beier UH, Wang L, Han R, Akimova T, Liu Y, Hancock WW. Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms. Sci Signal. 2012;5:ra45.","journal-title":"Sci Signal"},{"key":"517_CR20","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1128\/MCB.05155-11","volume":"31","author":"EF Zoeten de","year":"2011","unstructured":"de Zoeten EF, Wang L, Butler K, Beier UH, Akimova T, Sai H, Bradner JE, Mazitschek R, Kozikowski AP, Matthias P, Hancock WW. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol. 2011;31:2066\u201378.","journal-title":"Mol Cell Biol"},{"key":"517_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030815","volume":"7","author":"L Shen","year":"2012","unstructured":"Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P, Shrikant P, Fenstermaker R, Pili R. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS One. 2012;7:e30815.","journal-title":"PLoS One"},{"key":"517_CR22","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1158\/2159-8290.CD-16-1020","volume":"7","author":"DO Adeegbe","year":"2017","unstructured":"Adeegbe DO, Liu Y, Lizotte PH, Kamihara Y, Aref AR, Almonte C, Dries R, Li Y, Liu S, Wang X, et al. Synergistic Immunostimulatory effects and therapeutic benefit of combined histone deacetylase and Bromodomain inhibition in non-small cell lung Cancer. Cancer Discov. 2017;7:852\u201367.","journal-title":"Cancer Discov"},{"key":"517_CR23","doi-asserted-by":"crossref","unstructured":"Bae J, Hideshima T, Tai YT, Song Y, Richardson P, Raje N, Munshi NC, Anderson KC. Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. Leukemia. 2018.","DOI":"10.1038\/s41375-018-0062-8"},{"key":"517_CR24","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1084\/jem.20060468","volume":"203","author":"N Seddiki","year":"2006","unstructured":"Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med. 2006;203:1693\u2013700.","journal-title":"J Exp Med"},{"key":"517_CR25","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1126\/science.1079490","volume":"299","author":"S Hori","year":"2003","unstructured":"Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057\u201361.","journal-title":"Science"},{"key":"517_CR26","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1182\/blood-2013-03-492397","volume":"122","author":"A Veerapathran","year":"2013","unstructured":"Veerapathran A, Pidala J, Beato F, Betts B, Kim J, Turner JG, Hellerstein MK, Yu XZ, Janssen W, Anasetti C. Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host disease. Blood. 2013;122:2251\u201361.","journal-title":"Blood"},{"key":"517_CR27","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s10875-011-9508-8","volume":"31","author":"X Zhou","year":"2011","unstructured":"Zhou X, Hua X, Ding X, Bian Y, Wang X. Trichostatin differentially regulates Th1 and Th2 responses and alleviates rheumatoid arthritis in mice. J Clin Immunol. 2011;31:395\u2013405.","journal-title":"J Clin Immunol"},{"key":"517_CR28","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S0092-8674(00)80240-8","volume":"89","author":"W Zheng","year":"1997","unstructured":"Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell. 1997;89:587\u201396.","journal-title":"Cell"},{"key":"517_CR29","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S0092-8674(00)80702-3","volume":"100","author":"SJ Szabo","year":"2000","unstructured":"Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell. 2000;100:655\u201369.","journal-title":"Cell"},{"key":"517_CR30","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1158\/2326-6066.CIR-14-0159","volume":"3","author":"MM Berrien-Elliott","year":"2015","unstructured":"Berrien-Elliott MM, Yuan J, Swier LE, Jackson SR, Chen CL, Donlin MJ, Teague RM. Checkpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor-infiltrating CD8+ T cells. Cancer Immunol Res. 2015;3:116\u201324.","journal-title":"Cancer Immunol Res"},{"key":"517_CR31","doi-asserted-by":"publisher","first-page":"5709","DOI":"10.4049\/jimmunol.1401436","volume":"193","author":"I Popescu","year":"2014","unstructured":"Popescu I, Pipeling MR, Shah PD, Orens JB, McDyer JF. T-bet:Eomes balance, effector function, and proliferation of cytomegalovirus-specific CD8+ T cells during primary infection differentiates the capacity for durable immune control. J Immunol. 2014;193:5709\u201322.","journal-title":"J Immunol"},{"key":"517_CR32","doi-asserted-by":"publisher","first-page":"4068","DOI":"10.4049\/jimmunol.1002145","volume":"187","author":"NS Joshi","year":"2011","unstructured":"Joshi NS, Cui W, Dominguez CX, Chen JH, Hand TW, Kaech SM. Increased numbers of preexisting memory CD8 T cells and decreased T-bet expression can restrain terminal differentiation of secondary effector and memory CD8 T cells. J Immunol. 2011;187:4068\u201376.","journal-title":"J Immunol"},{"key":"517_CR33","first-page":"1803","volume":"8","author":"Q Jia","year":"2015","unstructured":"Jia Q, Yang Y, Wan Y. Tumor-infiltrating memory T-lymphocytes for prognostic prediction in cancer patients: a meta-analysis. Int J Clin Exp Med. 2015;8:1803\u201313.","journal-title":"Int J Clin Exp Med"},{"key":"517_CR34","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, Clark NR, Ma'ayan A. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14:128.","journal-title":"BMC Bioinformatics"},{"key":"517_CR35","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/ni.2867","volume":"15","author":"EB Heikamp","year":"2014","unstructured":"Heikamp EB, Patel CH, Collins S, Waickman A, Oh MH, Sun IH, Illei P, Sharma A, Naray-Fejes-Toth A, Fejes-Toth G, et al. The AGC kinase SGK1 regulates TH1 and TH2 differentiation downstream of the mTORC2 complex. Nat Immunol. 2014;15:457\u201364.","journal-title":"Nat Immunol"},{"key":"517_CR36","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.immuni.2014.10.013","volume":"41","author":"MM Staron","year":"2014","unstructured":"Staron MM, Gray SM, Marshall HD, Parish IA, Chen JH, Perry CJ, Cui G, Li MO, Kaech SM. The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. Immunity. 2014;41:802\u201314.","journal-title":"Immunity"},{"key":"517_CR37","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1158\/0008-5472.CAN-14-2277","volume":"75","author":"JG Crompton","year":"2015","unstructured":"Crompton JG, Sukumar M, Roychoudhuri R, Clever D, Gros A, Eil RL, Tran E, Hanada K, Yu Z, Palmer DC, et al. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res. 2015;75:296\u2013305.","journal-title":"Cancer Res"},{"key":"517_CR38","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/nature12297","volume":"499","author":"H Zeng","year":"2013","unstructured":"Zeng H, Yang K, Cloer C, Neale G, Vogel P, Chi H. mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Nature. 2013;499:485\u201390.","journal-title":"Nature"},{"key":"517_CR39","doi-asserted-by":"publisher","first-page":"7475","DOI":"10.1158\/0008-5472.CAN-08-1047","volume":"68","author":"AB Sherk","year":"2008","unstructured":"Sherk AB, Frigo DE, Schnackenberg CG, Bray JD, Laping NJ, Trizna W, Hammond M, Patterson JR, Thompson SK, Kazmin D, et al. Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic. Cancer Res. 2008;68:7475\u201383.","journal-title":"Cancer Res"},{"key":"517_CR40","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1158\/1535-7163.MCT-05-0005","volume":"4","author":"Y Luo","year":"2005","unstructured":"Luo Y, Shoemaker AR, Liu X, Woods KW, Thomas SA, de Jong R, Han EK, Li T, Stoll VS, Powlas JA, et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther. 2005;4:977\u201386.","journal-title":"Mol Cancer Ther"},{"key":"517_CR41","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S1470-2045(16)30375-8","volume":"17","author":"AJ Yee","year":"2016","unstructured":"Yee AJ, Bensinger WI, Supko JG, Voorhees PM, Berdeja JG, Richardson PG, Libby EN, Wallace EE, Birrer NE, Burke JN, et al. Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. Lancet Oncol. 2016;17:1569\u201378.","journal-title":"Lancet Oncol"},{"key":"517_CR42","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.4049\/jimmunol.1302778","volume":"193","author":"F Cheng","year":"2014","unstructured":"Cheng F, Lienlaf M, Wang HW, Perez-Villarroel P, Lee C, Woan K, Rock-Klotz J, Sahakian E, Woods D, Pinilla-Ibarz J, et al. A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3\/IL-10 pathway in APCs. J Immunol. 2014;193:2850\u201362.","journal-title":"J Immunol"},{"key":"517_CR43","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s12272-009-1418-4","volume":"32","author":"SB Han","year":"2009","unstructured":"Han SB, Lee JK. Anti-inflammatory effect of Trichostatin-a on murine bone marrow-derived macrophages. Arch Pharm Res. 2009;32:613\u201324.","journal-title":"Arch Pharm Res"},{"key":"517_CR44","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.canlet.2015.07.009","volume":"367","author":"MH Mannino","year":"2015","unstructured":"Mannino MH, Zhu Z, Xiao H, Bai Q, Wakefield MR, Fang Y. The paradoxical role of IL-10 in immunity and cancer. Cancer Lett. 2015;367:103\u20137.","journal-title":"Cancer Lett"},{"key":"517_CR45","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/intimm\/dxr029","volume":"23","author":"R Yagi","year":"2011","unstructured":"Yagi R, Zhu J, Paul WE. An updated view on transcription factor GATA3-mediated regulation of Th1 and Th2 cell differentiation. Int Immunol. 2011;23:415\u201320.","journal-title":"Int Immunol"},{"key":"517_CR46","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/ni1549","volume":"9","author":"Y Tone","year":"2008","unstructured":"Tone Y, Furuuchi K, Kojima Y, Tykocinski ML, Greene MI, Tone M. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol. 2008;9:194\u2013202.","journal-title":"Nat Immunol"},{"key":"517_CR47","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1084\/jem.20090226","volume":"206","author":"L Bruno","year":"2009","unstructured":"Bruno L, Mazzarella L, Hoogenkamp M, Hertweck A, Cobb BS, Sauer S, Hadjur S, Leleu M, Naoe Y, Telfer JC, et al. Runx proteins regulate Foxp3 expression. J Exp Med. 2009;206:2329\u201337.","journal-title":"J Exp Med"},{"key":"517_CR48","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.immuni.2011.08.012","volume":"35","author":"Y Wang","year":"2011","unstructured":"Wang Y, Su MA, Wan YY. An essential role of the transcription factor GATA-3 for the function of regulatory T cells. Immunity. 2011;35:337\u201348.","journal-title":"Immunity"},{"key":"517_CR49","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08155","volume":"460","author":"K Araki","year":"2009","unstructured":"Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, Larsen CP, Ahmed R. mTOR regulates memory CD8 T-cell differentiation. Nature. 2009;460:108\u201312.","journal-title":"Nature"},{"key":"517_CR50","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.4049\/jimmunol.1103568","volume":"188","author":"EH Kim","year":"2012","unstructured":"Kim EH, Sullivan JA, Plisch EH, Tejera MM, Jatzek A, Choi KY, Suresh M. Signal integration by Akt regulates CD8 T cell effector and memory differentiation. J Immunol. 2012;188:4305\u201314.","journal-title":"J Immunol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0517-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:46:15Z","timestamp":1601041575000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0517-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,6]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["517"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0517-0","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,6]]},"assertion":[{"value":"4 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All protocols were approved by the Institutional Review Board at H. Lee Moffitt Cancer Center (IRB 106509, 107,273; Tampa, FL), and cells were obtained under a Materials Transfer Agreement. Samples were coded with an anonymized 5-digit number and their identity was unknown to those performing the experiments.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Andressa S. Laino: Received one-year of grant funding from Acetylon Pharmaceuticals, in 2016.Brian C. Betts: The author declares no potential conflicts of interest.Anandharaman Veerapathran: The author declares no potential conflicts of interest.Igor Dolgalev: The author declares no potential conflicts of interest.Amod Sarnaik: Paid consultant for Iovance Biotherapeutics Inc. and B4CC Inc., and has received research funding support from Provectus, Iovance and Genentech.Steven N. Quayle: Former employee and stockholder of Acetylon Pharmaceuticals.Simon S. Jones: Former employee and stockholder of Acetylon Pharmaceuticals.Jeffrey S. Weber: Has stock or other ownership in Altor BioScience, Celldex, Biond and CytomX Therapeutics. Has honoraria in Bristol-Myers Squibb, Merck, Genentech, AbbVie, AstraZeneca, Daiichi Sankyo, GlaxoSmithKline, Eisai, Altor BioScience, Amgen, Roche, Ichor Medical Systems, Celldex, CytomX Therapeutics, Nektar, Novartis, Array, WindMIL, Takeda and Sellas. Has consulting or advisory role in Celldex, Ichor Medical Systems, Pieris Pharmaceuticals, Altor BioScience, Bristol-Myers Squibb, Merck, Genentech, Roche, Amgen, AstraZeneca, GlaxoSmithKline, Daiichi Sankyo, AbbVie, Eisai, CytomX Therapeutics, Nektar, Novartis, Array, WindMIL, Takeda and Sellas. Received research funding (to the Institution) from Bristol-Myers Squibb, Merck, GlaxoSmithKline, Genentech, Astellas Pharma, Incyte, Roche and Novartis. Received one-year of grant funding from Acetylon Pharmaceuticals. Received travel, accommodations, expenses from Bristol-Myers Squibb, GlaxoSmithKline, Daiichi Sankyo, Roche, Celldex, Amgen, Merck, AstraZeneca, Genentech, Novartis, Incyte, WindMIL and Takeda.David M. Woods: Received research funding from Mirati Therapeutics, in 2016 and 2017. Has stock in Bristol-Myers Squibb, Merck, GlaxoSmithKline, Seattle Genetics, Mirati Therapeutics, Iovance Biotherapeutics, Cue Biopharma, Fate Therapeutics, Atra Biotherapeutics, and Fortress Biotech.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"33"}}